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ABSTRACT
Introduction: Persistent pain is a major concern for
patients with psoriatic arthritis (PsA). Pain may be due
to inflammatory activity or augmented central pain
processing. Unawareness of the origin and
mechanisms of pain can lead to misinterpretation of
disease activity (by composite scores) and erroneous
treatments. Ultrasonography (US) is a highly sensitive
method to detect tissue inflammation. Evaluating pain
mechanisms in relation to US measures may prove
valuable in predicting response to treatment in PsA.
Aims: To study the association and prognostic value
of pain mechanisms, ultrasonic activity and clinical
outcomes in patients with PsA who intensify
antirheumatic treatment.
Methods and analyses: 100 participants >18 years
of age with PsA who initiate or switch antirheumatic
treatment (biologicals and/or conventional synthetic
disease-modifying antirheumatic drugs (DMARDs)) will
be prospectively recruited from outpatient clinics in
Copenhagen. All data (demographics, clinical, imaging,
blood samples and patient-reported outcomes) will be
collected at baseline and after 4 months. Pain is
assessed by the PainDETECT Questionnaire, Visual
Analogue Scale for pain, Swollen to Tender Joint Count
Ratio, Widespread Pain Index and tender point
examination. The association between pain variables and
clinical/US characteristics will be described by
correlation analyses. The predictive value of pain
measures and baseline US scores on treatment response
will be analysed with regression models. Outcomes are
composite and clinical, as well as patient reported.
Ethics and dissemination: The study is approved
by the ethics committee of the Capital Region of
Denmark (H-15009080) and has been designed in
cooperation with patient research partners. The study
is registered at clinicaltrials.gov (number
NCT02572700). Results will be disseminated through
publication in international peer-reviewed journals.
Trial registration number: NCT02572700, Pre-results.
INTRODUCTION
Psoriatic arthritis (PsA) is a heterogeneous
disease with a wide clinical spectrum and
diverse outcomes.1 Disease-modifying anti-
rheumatic drugs (DMARDs), including
biological treatments, have improved the
management of PsA substantially during the
past decades.2 Nevertheless, only around
half of the patients experience a sufficient
response from these drugs in routine care.3
Research of prognostic factors and treat-
ment response modifiers in PsA has pro-
vided valuable knowledge that could
theoretically improve treatment strategies
and overall prognosis.3–13 Nevertheless, the
majority of patients with PsA still consider
their disease to be severe and perceive the
treatment options as limited or burden-
some.14 Presumably, assessment of prognos-
tic profiles has to be more comprehensive
Strengths and limitations of this study
▪ Prospective and comprehensive investigation of
psoriatic arthritis (PsA) manifestations, ultrason-
ography and pain mechanisms in relation to
treatment outcomes.
▪ Focus on patient-reported outcomes in ‘real-life’
observational settings.
▪ Involvement of several specialties and patient
research partners.
▪ Results should be interpreted in the context of
the explorative study design and the use of
outcome measures that are not (sufficiently) vali-
dated for PsA.
▪ Heterogeneity of the study population may limit
the analyses.
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and include patient-related concerns, motives and psy-
chological aspects in order to optimise the clinical
benefit. Seen from this aspect, the focus on pain seems
relevant. Pain has been endorsed as a core domain in
the assessment of PsA by the Group for Research
and Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) and Outcome Measures in Rheumatology
(OMERACT) initiative.15 Patients with PsA report pain
to be their utmost priority and major health concern,
while this symptom may be underestimated by clini-
cians.16–18 Little is known about pain mechanisms in
PsA.19–22 The complex disease spectrum and lack of
valid inflammatory biomarkers challenge the clinical
evaluation and interpretation of pain reporting in PsA
in which the widespread and persistent pain may be
caused by augmented pain processing as a conse-
quence of central sensitisation (CS).22 Clinically CS is
thought to account for neuropathic pain features such
as secondary hyperalgesia, burning and prickling sensa-
tion, allodynia, pain attacks/electric shocks and pain
evoked by slight pressure. These are also common pain
qualities in patients with fibromyalgia23 and frequently
reported by rheumatic patients.24–26 In some indivi-
duals, CS seems to develop into a state of chronic wide-
spread pain (CWP) fully uncoupled from inflammatory
activity. The mechanisms behind CWP is sparsely eluci-
dated but may involve maladaptive neuroplasticity and
cortical reorganisation of the somatosensory and motor
systems,26 27 aberrant peripheral inputs to central
nervous system,28 modulation of glia cell function,29
and disruption of descending inhibitory and facilitating
control.30 31 An alternative explanation for ongoing
pain could be obscure, untargeted inflammation of
psoriatic loci not (always) assessed in routine rheuma-
tology care such as entheses, skin and tendons.
Besides, these manifestations seem less responsive to
conventional disease-modifying drugs than synovitis of
the joints.2 32 High-frequency ultrasound is increasingly
being used for the evaluating of inflammatory arthritis,
including PsA, since this method exhibits sensitivity for
assessing disease activity and structural damage com-
pared with clinical examination.33–36 Synovial hyper-
trophy and effusions are examined by grey scale (GS)
ultrasound and the neovascularisation within the
inflamed structures can be visualised by ultrasound
Doppler activity (USD). In PsA, the value of ultrasonog-
raphy (US) as a prognostic factor has been sparsely
investigated to date. In patients with psoriasis, studies
have documented that US activity in entheses, for
example, is associated with an increased risk of devel-
oping PsA.37–39 In rheumatoid arthritis (RA), subclin-
ical arthritic activity determined by US seems to
provide valuable prognostic insight into the risk of
structural damage40 as well as the chance of treatment
response,41 and recent studies have emphasised the
benefit of US compared with composite clinical scores
in the clinical evaluation of RA with concomitant
fibromyalgia.42 43
RATIONALE AND THEORETICAL CONSIDERATIONS
Incomplete awareness of underlying pain mechanisms
may influence the assessment and management of PsA
in several ways. Augmented central pain processing in
PsA generates continuous reporting of high pain, dis-
ability and overall poor health.16 44–46 This may specific-
ally lead to misinterpretation of composite disease
outcome measures, which then increases the risk of
redundant conventional synthetic and/or biologicals
DMARD (cs/bDMARD) treatment and insufficient pain
management. In other cases, poor patient-reported out-
comes and ongoing pain may be generated by untar-
geted (subclinical) psoriatic disease activity, which
should not be interpreted as a ‘chronic pain syndrome’.
A thorough examination of pain mechanisms combined
with an evaluation of inflammatory activity by US
imaging and clinical examination may improve our
interpretation of PsA disease expressions.
Aims: The primary aim is to investigate pain mechan-
ism in PsA, and elucidate associations between pain
outcome measures and clinical characteristics, with a
special emphasis on US inflammatory activity. The study
further aims to explore response rates to cs/bDMARD
therapy in PsA subgroups (eg, according to pain profile,
baseline US scores or treatment intervention), and
analyse the predictive value of US scores and pain
mechanisms on response to cs/bDMARD treatment.
We hypothesise that US assessment will be a valuable
tool to improve the interpretation of pain outcome mea-
sures in PsA, and that pain mechanisms and/or US
scores are of value in predicting response to anti-
inflammatory treatment
PATIENTS RESEARCH PARTNERS (PRPS)
The observational, clinical settings of the study ensure a
high external validity. Furthermore, the study is
designed with assistance from a professional, inter-
national PRP (co-author MdW) and two Danish
PRPs (Connie Haugaard (CH) and co-author KB).
Collaboration between patients and professionals in
developing and disseminating research projects is rela-
tively new. Nevertheless, this project follows the EULAR
recommendations47 for the inclusion of patient represen-
tatives in the contemporary scientific process by adhering
to eight important aspects as depicted in table 1.
METHODS
Study design
A cohort of patients with PsA initiating antirheumatic
treatment in routine care will prospectively be enrolled
in the Non-Intervention-Study (NIS) framework. All par-
ticipants will be assessed at baseline and after 4 months
(follow-up). The baseline visit is defined as the time
window from 14 days before until 7 days after initiation/
switch of cs/bDMARD treatment. The enrolment period
will be from 17 September 2015 to 1 February 2017.
Follow-up will be completed by 15 June 2017. All
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examinations will be carried out at The Parker Institute,
Frederiksberg Hospital, the Capital Region of Denmark.
Participants
Patients with a diagnosis of PsA who may be considered
for inclusion will be identified during routine care at
Departments of Rheumatology in the Capital Region of
Denmark. The primary study investigator will determine
whether the eligibility criteria are fulfilled. Patients of at
least 18 years of age and diagnosed with PsA by a
rheumatologist and fulfil the CASPAR classification cri-
teria48 are considered for inclusion if they present with
peripheral joint involvement and are about to initiate or
switch csDMARD or bDMARD treatment due to active
PsA. Written informed consent is acquired. Patients are
excluded in case of pregnancy, peripheral neuropathy,
demyelinating disease, recent stroke or other rheumatic
inflammatory diseases. Patients who suffer from axial
PsA without peripheral manifestations are excluded and
patients treated with oral, intra-articular or intramuscu-
lar glucocorticoids within the past 3 weeks, centrally
acting analgesics (opioids, antidepressants,
anticonvulsants) during the past week or mild analgesics
(non-steroidal anti-inflammatory drugs, acetylsalicylic
acid, acetaminophen) 24 h prior to baseline are not
includable. During the study period, the patients will
receive routine care as decided by their treating rheuma-
tologist, with prospective registrations in the Danish
DANBIO registry according to Danish standard for clin-
ical practise.49 All relevant interventions will be regis-
tered in the study.
Variables and outcome measures
Participants will undergo an examination programme to
assess the variables of interest (table 2).
Clinical examination
Two trained healthcare professionals will perform the
interview and clinical examination, which consist of
(table 2): a 66/68 swollen/tender joint count ad
modum EULAR; the Spondyloarthritis Research
Consortium of Canada enthesitis score (SPARCC)50
evaluating tenderness in 18 entheses sites, with a
maximum score of 16; number of fingers and toes
affected by dactylitis (present/not present); tender
point examination according to the 1990 American
College of Rheumatology (ACR) criteria for fibromyal-
gia;51 psoriatic nail disease (yes/no, y/n); psoriasis body
surface area (BSA); type of psoriasis and Psoriatic Area
Severity Index (PASI) in psoriasis vulgaris. Height and
weight will be measured as well. An Assessment of Motor
and Process Skills (AMPS test) will be performed by a
calibrated occupational therapist who has attended a
specialised training course in the standardised AMPS
administration procedures.52
Blood samples
Blood samples, as specified in table 2, will be collected
and processed by a trained laboratory technician and
analysed according to standard procedures. All samples
will be anonymised by a coding procedure and destroyed
at study completion.
Assessment of pain mechanisms
Characterisation of pain profiles will be based on the fol-
lowing assessment tools:
1. The PainDETECT Questionnaire (PDQ) was devel-
oped and validated in 2006 for the purpose of estab-
lishing a patient-administered screening tool to
detect the likelihood of a neuropathic pain compo-
nent in patients with low back pain.46 Research of
neuropathic pain features in other chronic pain and
rheumatic conditions has expanded the applicability
of PDQ.23 24 53 54 The PDQ consists of nine items of
which seven are somatosensory descriptor items, and
two items relate to the spatial (radiating) and tem-
poral pain characteristics. For screening purposes,
PDQ cut-off scores ≤12 (a neuropathic component is
unlikely) and ≥19 (a neuropathic component is
likely) have been found to be appropriate.46
Table 1 PRP involvement according to EULAR
recommendations
1 PRPs (CH KB and MdW) have voluntarily participated
in the process of designing and preparing the study
protocol. They have acknowledged the protocol in its
current form.
2 The PRPs have acknowledged the idea and purpose of
the study, and participated in discussions of ethics,
design, relevance and feasibility of the content and
investigation programme. They have revised all patient
information prior to distribution. PRPs and primary
investigator (PH) will meet approximately every 6th
month until the study is finalised to discuss the
process.
3 The PrPs suffer from psoriasis and concomitant
psoriatic arthritis. One is young (20 years), while the
others are middle aged.
4 The 2 Danish PRPs were identified during routine care.
Prior to their decision of participation, they received a
written and oral task description that clarified their roles
and expected contributions.
5 The PRP exhibited immense interest in the research
collaboration and showed good communication skills.
6 The primary investigator will continuously consider the
specific needs of the PRP, including educational
aspects. A safe and respectful environment is highly
prioritised and the PRP may contact the research
group whenever needed.
7 The investigators provide information and appropriate
training, including awareness of ethical issues
continuously throughout the study.
8 The PRP work voluntarily and have been offered
coauthorship according to the International Committee
of Medical Journal Editors criteria.
PRP, patient research partner.
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Table 2 Examination and interview at baseline and follow-up
Baseline 4 Months
Demographics and disease-related characteristics (interview)
Sex(M/F) X
Age (years) X
Diagnosed with spinal involvement (y/n) X
Disease duration of psoriatic arthritis (months) X
Symptom duration prior to diagnosis (months) X
Disease duration of psoriasis (months) X
Educational level X
Smoking (current/previous/never) X
Alcohol consumption (number per week) X
Diabetes (y/n) X
Cardiovascular disease (y/n) X
Dyslipidaemia (or treatment for this) (y/n) X
Mental disorder (depression, anxiety) (y/n) X
Medication (interview)
Use of mild analgesics, including NSAIDs (dosage) X X
Use of opioids, antidepressants or anticonvulsants during the study period (dosage) X
Cumulated dose of oral prednisolone during the last month X X
Medication history (current and previous cs/bDMARD) X
Interval (days) between study baseline visit and initiation of new treatment X
Date for treatment termination of new drug X
Reason for treatment withdrawal during the study period (lack of effect, adverse events, other) X
Clinical examination
VAS physician (0–100) X X
Height (cm) X
Weight (kg) X
Swollen joint count (66)(number) X X
Tender joint count (68)(number) X X
Manual tender point examination (number), only scores ≥2 are interpreted as a tender point. X X
SPARCC X X
Dactylitis (number) X X
Psoriatic body surface area (%) X X
Subtype of psoriasis X
Psoriatic nail lesions (number) X X
PASI (if psoriasis vulgaris) X X
Patient-reported outcomes
PDQ score X X
HAQ Disability Index (HAQ, including VAS for pain and global) X X
Medical Outcomes Study Questionnaire (SF-36, mental and physical) X X
PsAID X X
DLQI X X
VAS fatigue (0–100) X X
AMPS X X
WPI X X
GAD-10 X X
Trans-Q score X
BASFI X X
BASDAI X X
Imaging
X-ray hands and feet X
Ultrasonographic examination X X
Blood samples (maximum 54 mL at each time point)
Blood samples will be analysed for: C reactive protein, ALAT, alkaline phosphatase, erythrocytes,
erythrocytes volume fraction, erythrocyte MCV, haemoglobin, erythrocyte MCHC, leucocytes and leucocyte
types, reticulocytes, thrombocytes, potassium, sodium, creatinine, cobalamin (B12), VitD (P-25(OH)D
cholesterol (total), LDL, HDL, glucose, HbA1C, inflammatory biomarkers.
X X
ALAT, alanine aminotransferase; AMPS, Assessment of Motor and Process Skills; BASDAI, Bath Ankylosing Spondylitis Disease Activity
Index; BASFI, Bath Ankylosing Spondylitis Functional Index; cs/bDMARD, conventional synthetic and/or biologicals disease-modifying
antirheumatic drugs; DLQI, Dermatology Life Quality Index; GAD-10, Generalised Anxiety Disorder Self-Assessment Questionnaire; HAQ,
Health Assessment Questionnaire; HbA1C, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; M/F, male/
female; MCHC, mean corpuscular haemoglobin concentration; MCV, mean cell volume; PASI, Psoriatic Area Severity Index; PDQ,
PainDETECT Questionnaire; PsAID, Psoriatic Arthritis Impact of Disease score; SPARCC, Spondyloarthritis Research Consortium of Canada
enthesitis score; Trans-Q, Transition Questionnaire; VAS, Visual Analogue Scale; WPI, Widespread Pain Index; y/n, yes/no.
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2. The Widespread Pain Index (WPI) constitutes part of
the 2010 diagnostic criteria for fibromyalgia. From a
list of 19 body parts supported by an explanatory
body diagram, patients are able to indicate in which
of the 19 areas they have had pain during the last
week, corresponding to a WPI score between 0 and
19. A score above 7 is interpreted as a widespread
pain indicium.55
3. The Swollen to Tender Joint Count Ratio (SJ/TJ) has
been explored in a cohort of >2500 patients with RA
who initiated anti-tumour necrosis factor-alpha treat-
ment. Patients presenting with a SJ/TJ count ratio
>0.5 were 2–3 times more likely to respond to treat-
ment.56 The relevance of SJ/TJ ratio has not been
investigated in PsA before. The SJ/TJ ratio in this
study will be based on maximum 66 SJ and 66 TJ
(excluding tenderness of the hips).
4. The tender point count is part of the 1990 ACR cri-
teria for fibromyalgia (FM), where the cut-off is 11 of
the 18 tender points (in combination with pain in 3
body quadrants).51 A study of PsA found that features
with the greatest discriminating power for FM were a
tender point count ≥8 tender points and ≥6
FM-associated symptoms.22
Imaging
No gold-standard ultrasound (US) algorithm has yet
been accepted for assessing disease activity in PsA. With
the purpose of achieving a visualised measure of the
composite psoriatic disease activity, we will apply a sys-
tematic US examination that assesses inflammatory
changes in 26 joints (13 unilateral) of upper and lower
extremities, and 12 entheses/tendons (6 unilateral) as
shown in table 3. US examination of wrists, knees and
metacarpophalangeal (MCP), metatarsophalangeal
(MTP), proximal (PIP) and distal (DIP) interphalangeal
joints of hands and feet will be performed by two experi-
enced sonographers blinded to the patients clinical and
laboratory data. The images of all patients will be saved
in a digital archiving computer system for subsequent
scoring. The scoring of US pathology will follow a pre-
specified procedure made in accordance with the
OMERACT definitions and previously published scoring
systems.57–60 Joints will be assessed for synovial hyper-
trophy, Doppler activity and erosions, whereas scoring of
entheses/tendons will adhere to the Madrid
Sonographic Enthesitis Index (MASEI) algorithm.61
Scanning will be performed with a General Electric
Logiq E9 (Milwaukee, Wisconsin, USA) using a linear
array matrix transducer with a 15 MHz centre frequency.
The interobserver reliability of the two sonographers
will be investigated by double scans of patient 6–35. US
assessment will occur on the same day as the clinical
examination.
Radiographic images (X-rays) of the hands and feet
will be taken at study start and evaluated for psoriatic
changes by a radiologist, unless radiographic images and
descriptions from the past 6 months are available from
the hospital files.
Patient demographics and patient-reported outcomes
Patient demographics and medication profile will be col-
lected from the participants through the interview and
from the patients’ files. Patient-reported outcomes will
be obtained from electronic questionnaires (table 2)
accessible from computer touch screens at the study
site.62 Besides pain assessment questionnaires, the
following questionnaires will be presented to the
participants.
The Psoriatic Arthritis Impact of Disease score (PsAID)
is a newly developed, prevalidated patient-derived and
patient-reported outcome measure (0–10 scale) for
assessment of pain, skin, fatigue, work/leisure activities,
function, discomfort, sleep, coping and anxiety.18
The Medical Outcomes Study SF-36 (SF-36) is a
generic health status questionnaire developed as a tool
to compare various aspects of health status across a
general and broad patient population. We will use the
Danish version of SF-36 which uses a 4-week recall
period. Both the Physical Component Summary (PCS)
and the Mental Component Summary (MCS) scores will
be assessed.63
The Health Assessment Questionnaire (HAQ) is used
for assessing limitations in daily living activities. It
Table 3 Ultrasonographic assessment of joints, tendons and entheses
Tendons and joints Entheses
Assessments (scores) Loci Assessments (scores) Loci (mm*)
Synovial hypertrophy (0–3) MCP 2–3 (D/V) Structure (±) Quadriceps ligament (<6.1)
Synovial Doppler (0–3), PIP 2–3 (D/V) Thickness (±) Patella proximal ligament
Tendon thickness (±), DIP 2–3 (D/V) Calcification (0–3) (<4) Patella distal ligament (<4)
Tendon Doppler (±), Wrist (D/V) Doppler (0–3) Fascia plantaris (<4.4)
Erosions (0–3). Knee (M/L) Bursitis (±). Achilles tendon (<5.29)
MTP-D 1–3 Triceps tendon (<4.3)
DIP-D 2–3 (foot)
*Normal tendon thickness.
D, dorsal; DIP, distal interphalangeal; L, lateral; M, medial; MCP, metacarpophalangeal; MTP, metatarsophalangeal; PIP, proximal
interphalangeal; V, volar.
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consists of 20 questions addressing eight different areas
of functional ability, and yields a total score between 0
and 3, with a higher score representing increasing dis-
ability.64 It was originally developed for RA, but is now
validated and widely used in PsA.65 66
Dermatology Life Quality Index (DLQI) is a
dermatology-specific health-related quality of life ques-
tionnaire. It consists of 10 questions concerning symp-
toms and feelings, daily activities, leisure, work, personal
relationships and treatment. Each question is scored
0–3, giving a sum ranging from 0 (no impairment of life
quality) to 30 (maximum impairment) for the total
score.67
The Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) comprises six Visual Analogue Scale
(VAS) items regarding fatigue, pain and stiffness. It was
developed for assessment of spinal disease in ankylosing
spondylitis, but has been adopted in the evaluation of
axial PsA disease.68 The Bath Ankylosing Spondylitis
Functional Index (BASFI) is a validated index to deter-
mine functional limitation in patients with ankylosing
spondylitis and has subsequently been implemented for
the assessment of spondyloarthropathies. It comprises of
10 questions regarding everyday life activities.
The Generalised Anxiety Disorder Self-Assessment
Questionnaire (GAD-10) is a 10-item questionnaire
developed from the Hamilton six-item anxiety scale. The
instrument measures generalised anxiety according to a
severity scale ranging from 0 to 50. A score of 15–19,
20–29 and 30–50 points indicate mild, moderate and
severe anxiety, respectively.69
The Transition Questionnaire (Trans-Q) consists of
three main questions addressing whether there has been
an improvement, deterioration or no change regarding
pain, function and overall condition between the two
visits.70
Exploratory outcomes and response criteria
Response to treatment during the 4-month study period
will be assessed by various outcome variables covering
composite, clinician-reported and patient-reported mea-
sures. Some of these outcomes are not validated for PsA,
but are included based on their extensive use in trials
and routine care of PsA. These are described in the fol-
lowing section. Clinician-reported and patient-reported
outcomes are shown in table 4.
Psoriatic Arthritis Disease Activity Score (PASDAS)71 is
a weighted index comprising assessments of joints, func-
tion, acute-phase response, quality of life, and patient
and physician global disease evaluation by VAS. The
score range of the PASDAS is 0–10, with worse disease
activity represented by higher scores. Cut-off values for a
PASDAS good/moderate/poor response has been elabo-
rated.72 In the current study, the original PASDAS will
be slightly modified (mPASDAS) by substituting assess-
ment of the entheses at the medial femur condyle with
that of the proximal patella. The latter site is included
in the SPARCC (already part of the examination
programme) and does not overlap with the location of a
tender point. Both the change in mPASDAS as well as
achievement of mPASDAS good response (score <3.2
and an improvement in score of >1.6) will be evaluated.
The Disease Activity index for Psoriatic Arthritis
(DAPSA) is the summation of the following five vari-
ables: Patient's global assessment, Patient's pain assess-
ment (both on 10 cm VAS scales), Swollen joint count
(0–66), Tender joint count (0–68) and C-reactive
protein (CRP). DAPSA was originally developed for
reactive arthritis (named ‘DAREA’), but evidence has
been provided for the utility and validity of the DAPSA
for PsA disease activity assessment.73 Furthermore,
DAPSA correlates with ultrasound disease activity,59 and
the cut-offs for disease activity states and treatment
response criteria have recently been provided.74
Table 4 Outcome measures assessed 4 months’ after
baseline
Composite
outcome
ACR 20%/50%/70% response
MDA
DAPSA
DAPSA 50%/75%/85% response
Δ CDAI
Δ DAS28
mPASDAS good response
Δ mPASDAS
Clinical
outcomes
Δ SPARCC enthesitis score
Δ Dactylitis (number)
Δ Number of tender and swollen joints
Δ PASI
Δ CRP level
Δ Physician’s global assessment
(VAS global)
Δ Ultrasonic score
Δ AMPS
Patient-reported
outcomes
Δ VAS-fatigue, Δ VAS-pain, Δ patient
VAS-global
Δ PSAID
Δ BASDAI
Δ BASFI
Δ SF-36 physical and mental summary
scores (PCS, MCS)
Δ HAQ-DI scores
Δ DLQI
Δ WPI
Δ GAD-10
Trans-Q score
Δ, change; ACR, American College of Rheumatology response
criteria; AMPS, Assessment of Motor and Process Skills; BASDAI,
Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath
Ankylosing Spondylitis Functional Index; CDAI, Clinical Disease
Activity Index; CRP, C reactive protein; DAPSA, Disease Activity
Index for Psoriatic Arthritis; DAS28, Disease Activity Score 28;
DLQI, Dermatology Life Quality Index; GAD-10, Generalised
Anxiety Disorder Self-Assessment Questionnaire; HAQ-DI, Health
Assessment Questionnaire Disability Index; MDA, Minimal
Disease Activity; mPASDAS, modified Psoriatic Arthritis Disease
Activity Score; PASI, Psoriatic Area Severity Index; SF-36, 36-
Item Short Form Health Survey; SPARCC, Spondyloarthritis
Research Consortium of Canada enthesitis score; Trans-Q,
Transition Questionnaire; VAS, Visual Analogue Scale; WPI,
Widespread Pain Index.
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The ACR response criteria75 were developed as mea-
sures of treatment response in trials of RA and has been
adopted in PsA, where it has shown good discriminatory
capacity.76 It has a dichotomous outcome (y/n) based
on the percentage of improvement in tender and
swollen joint counts, and in at least three of the follow-
ing five parameters: patients assessment, physician assess-
ment, pain scale, physical function, and acute-phase
reactant (CRP). The patient may fulfil a 20%, 50% or
70% improvement in these variables.
Minimal disease activity (MDA) criteria has been devel-
oped and validated with the objective of implementing
treat-to-target strategies and achieving remission in PsA.77
A patient is classified as having MDA when they meet five
of seven of the following criteria: tender joint count ≤1,
swollen joint count ≤1, PASI≤1 or BSA≤3 patient pain
VAS≤15 mm (0–100 mm), patient global activity
VAS≤20 mm, HAQ≤0.5, tender entheseal points ≤1.
Disease Activity Score 28 (DAS28) is widely used to
assess PsA disease activity in clinical settings and has
shown good discriminatory capacity in PsA studies,
although this composite score was originally developed
for RA.76 78 DAS28-CRP includes a 28 swollen joint and
tender joint count in addition to CRP level and a global
health scale.
Clinical Disease Activity Index (CDAI) is a simple
measure of disease activity that sums the patient’s and
physician’s global assessments, and a swollen and a
tender joint count. It is formally validated for RA, but
not for PsA.79 As with DAS28, the regular assessment of
CDAI in routine PsA care makes it relevant as an
exploratory outcome in the current study.
ANALYSES AND STATISTICS
Sample size considerations
Owing to the exploratory design, no statistical power cal-
culation has been performed. The study period is
limited to 17 months, which presumably allows us to
enrol 100 patients.
Descriptive statistics and main analyses
The study results will be reported in accordance with the
STROBE statement.80 Missing data at follow-up will be
imputed by a non-responder assumption (applying base-
line observation carried forward technique for continu-
ous data). Baseline variables will be described for all
participants and in relevant subgroups (eg, according to
treatment, pain profile or US activity). Means and SDs or
medians and IQRs will be calculated depending on data
distribution and comparisons will be performed by χ2 test
for categorical data and Mann-Whitney or Kruskal-Wallis
test for continuous data. p Values <0.05 are considered to
be statistically significant. The total number of partici-
pants with recorded values will be reported. Correlations
will be explored by Spearman’s rank-order correlation.
Achievement of patient, clinician and composite
response measures will be described for all patients and
in subgroups (eg, according to treatment, pain profile,
US activity). Regression models will be applied to study
if pain measurements and/or ultrasonic activity have an
impact on the treatment response measures (table 4).
Crude and adjusted estimates will be reported.
DISCUSSION
Patients suffering a chronic (rheumatic) disease need to
be aware of how various factors might influence their
prognosis in order to understand their disease course.
This insight will encourage patients and healthcare pro-
viders to intervene against modifiable adverse factors
and optimise/personalise treatment strategies based on
shared decision-making. The proposed study will
explore and provide insight into the presence and prog-
nostic impact of aberrant pain processing, and US
assessed inflammatory load in PsA. Pain is a dominant
and persistent symptom in PsA and is not uniformly cor-
related to routine measures of inflammatory activity.
Investigating the underlying mechanisms responsible for
this phenomenon will help clinicians to comprehend
reasons for persistent pain, interpret composite disease
activity scores, optimise patient counselling, and select
the most optimal treatment strategies. To the best of our
knowledge the impact of pain mechanisms in combin-
ation with US inflammatory assessment of treatment
response constitute a novel prognostic research focus in
PsA. A detailed study programme based on interview,
multidisciplinary clinical examination, imaging and
questionnaires will provide a thorough evaluation of the
PsA cohort and include, among other factors, the core
domains endorsed by OMERACT in 2006 for PsA assess-
ment in randomised control trial and observational
studies. The PsA core outcome set is currently undergo-
ing a revision (according to the OMERACT filter 2.0) in
order to enhance patients’ perspectives and reflect
recent insight into PsA disease. As part of this process,
an overview of the measurement properties and feasibil-
ity of instruments used for PsA will be performed with
the aim of endorsing at least one appropriate measure-
ment instrument per core domain.81–83 The current
study complies with the intention of GRAPPA and
OMERACT to incorporate patients’ perspectives into the
assessment and evaluation of PsA47 83–85 by examining
various patient-reported outcomes and by the participa-
tion of PRPs. Nevertheless, our study also reflects the
need for valid instruments (gold standards) to assess
PsA; several of the included outcome measures are not
validated for PsA, which is a limitation that must be kept
in mind when interpreting the results. However, we find
this strategy acceptable and appropriate given the lack of
gold standards, the multifaceted nature of PsA and the
limited knowledge currently available in this research
field. In conclusion, the proposed study will shed light
on associations and prognostic impact of pain mechan-
isms, and US-assessed inflammatory activity in patients
with PsA followed in routine care.
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